Fortress Companies

Home » Fortress companies » aevitas therapeutics

Aevitas Therapeutics

Aevitas Therapeutics, Inc. (Aevitas), a Fortress Biotech Company, is developing novel gene therapy approaches for complement-mediated diseases. The Company was formed based on technology that uses adeno-associated virus (AAV)-based gene therapy to restore lasting production of regulatory proteins, potentially providing a curative treatment for diseases with high unmet need. As regulators of the alternative pathway, irregularities in these proteins can play a vital role in numerous complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Recent research has also suggested that complement regulatory proteins could play a key role in the pathogenesis of age-related macular degeneration. Aevitas is headquartered in New York City.